Joshua DiNapoli received his PhD in Microbiology and Immunology from the University of Rochester in 2005, where he performed work in the lab of Dr. Robert C. Rose on virus-like particle vaccines against human papillomavirus. He went on to perform his post-doctoral work in the lab of Dr. Peter L. Collins at the National Institute of Allergy and Infectious Diseases from 2005 to 2010 where he developed live-attenuated vaccine candidates against RSV, highly pathogenic avian influenza, severe acute respiratory syndrome-associated coronavirus, and Ebola virus. He joined Sanofi Pasteur R&D in 2010, and has held various roles since that time, including Research Lead on the Broadly Protective Influenza Vaccine program, Head of North America B Cell Immunology/Antibody Discovery, Head of North America Biomarker Discovery and Development, Sanofi Research Representative on the Nirsevimab/Beyfortus project team, and most recently Global Project Head - mRNA Platform Development.
There are a wide variety of RNA molecules used to inhibit infectious diseases and cancer, a discussion of the common challenges in: